United Therapeutics Corp (UTHR) 106.50 $UTHR
Insider Trading Alert - K, EQR And UTHR Traded By Insiders
at The Street - Thu May 08, 11:16AM CDT
Stocks with insider trader activity include K, EQR and UTHR
Neuroblastoma Pipeline Review 2014: 32 Companies & 73 Drug profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pzz2k/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - United Therapeutics Corporation - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Celgene Corporation - AEterna Zentaris Inc. - Lixte Biotechnology Holdings, Inc. - Lorus Therapeutics Inc. - Novogen Limited - Threshold Pharmaceuticals, Inc. - Sareum Holdings plc - MabVax Therapeutics, Inc. - Bionucleon Srl - CerRx, Inc. - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - APEIRON Biologics AG - Xcovery, Inc. - Sutro Biopharma, Inc. - Incuron, LLC - Errant Gene Therapeutics, LLC - DEKK-TEC, Inc. - Bexion Pharmaceuticals, LLC. - Cancer Prevention Pharmaceuticals, Inc. - CureFAKtor Pharmaceuticals. LLC For more information visit http://www.researchandmarkets.com/research/9p...roblastoma
Synthetic Genomics Inc. Signs Collaborative Research and Development Agreement with Lung Biotechnology Inc., a Subsidiary of United Therapeutics Corporation, to Develop Humanized Pig Organs to Revolutionize Transplantation Field
PR Newswire - Tue May 06, 5:00AM CDT
Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Lung Biotechnology Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), today announced they have entered into a multi-year research and development agreement to develop humanized pig organs using synthetic genomic advances. The collaboration will focus upon developing organs for human patients in need of transplantation, with an initial focus on lung diseases. As part of the agreement SGI will receive royalties and milestone incentives from the development and commercialization of the organs.
3 Biotech Stocks Making Big Moves Last Week
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Biotech investors have been taken on a roller coaster ride over the past few months as stratospheric gains in the fourth and first quarters have been realized to pay tax bills and rebalance to other industries. While Foolish investors should never...
United Therapeutics Set to Possibly Pullback After Yesterday's Rally of 2.25%
Comtex SmarTrend(R) - Mon May 05, 5:02PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $102.14 to a high of $106.70. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $104.83 on volume of 995,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 2.25% Gain
Comtex SmarTrend(R) - Mon May 05, 5:01PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $102.14 to a high of $106.70. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $104.83 on volume of 995,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
United Therapeutics Gains on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:10PM CDT
United Therapeutics' (UTHR) first quarter earnings were significantly above expectations.
United Therapeutics Larger Than S&P 500 Component Integrys Energy Group
TheOnlineInvestor.com - Wed Apr 30, 3:47PM CDT
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component United Therapeutics Corp was identified as having a larger market cap than the smaller end of the S&P 500, for example Integrys Energy Group Inc ,...
Look for Shares of United Therapeutics to Potentially Pullback after Yesterday's 6.13% Rise
Comtex SmarTrend(R) - Tue Apr 29, 5:15PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $89.57 to a high of $96.24. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $94.68 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
United Therapeutics Corporation Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 5:00AM CDT
-- Revenues of $289.4 million
12.2% Return Seen to Date on SmarTrend United Therapeutics Call (UTHR)
Comtex SmarTrend(R) - Mon Apr 28, 9:19AM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on January 31st, 2014 at $103.65. In approximately 3 months, United Therapeutics has returned 12.15% as of today's recent price of $91.05.
Technical Roundup on Health Care Stocks -- Research on Amarin, United Therapeutics, Hologic, and NxStage Medical
PR Newswire - Fri Apr 25, 1:10PM CDT
On Thursday, April 24, 2014, the NASDAQ Composite ended at 4,148.34, up 0.52%, the Dow Jones Industrial Average finished the day flat at 16,501.65, and the S&P 500 closed at 1,878.61, up 0.17%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.80, down 0.20%, while the index has advanced 0.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR), Hologic Inc. (NASDAQ: HOLX) and NxStage Medical Inc. (NASDAQ: NXTM). Free technical research on AMRN, UTHR, HOLX and NXTM can be downloaded upon signing up at:
Product Clearance, Appointments, Upcoming Financial Results, and Clinical Study Results - Analyst Notes on Covidien, Medivation, United Therapeutics, Questcor and CareFusion
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Medivation, Inc. (NASDAQ: MDVN), United Therapeutics Corporation (NASDAQ: UTHR), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1611-100free.
Global Hypertension Drugs Market 2014-2018 with Actelion, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Dominating
M2 - Thu Apr 24, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brq49m/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies. The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/brq49m/global
United Therapeutics Corporation To Announce First Quarter 2014 Financial Results Before Market Open On Tuesday, April 29, 2014
PR Newswire - Tue Apr 22, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2014 financial results before market open on Tuesday, April 29, 2014.
Global Neuroblastoma Clinical Trials Review 2014 - Analysis of 9 Companies
M2 - Wed Apr 16, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfcrvd/neuroblastoma) has announced the addition of the "Neuroblastoma Global Clinical Trials Review, H1, 2014" report to their offering. Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials - Progenics Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - APEIRON Biologics AG - United Therapeutics Corporation - Cancer Prevention Pharmaceuticals, Inc. - MabVax Therapeutics, Inc. - Eli Lilly and Company - Celgene Corporation - Biotec Pharmacon ASA For more information visit http://www.researchandmarkets.com/research/hf...roblastoma
United Therapeutics Shares Down 8.1% Since SmarTrend's Sell Call (UTHR)
Comtex SmarTrend(R) - Mon Apr 14, 11:22AM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on January 31st, 2014 at $103.65. In approximately 2 months, United Therapeutics has returned 8.15% as of today's recent price of $95.20.
United Therapeutics Rises 3.89% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 09, 4:31PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.93 to a high of $98.45. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $95.28 on volume of 824,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of United Therapeutics to Potentially Pullback after Yesterday's 3.89% Rise
Comtex SmarTrend(R) - Wed Apr 09, 4:31PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.93 to a high of $98.45. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $95.28 on volume of 824,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Insider Trading Alert - K, EQR And UTHR Traded By Insiders
at The Street - Thu May 08, 11:16AM CDT
Stocks with insider trader activity include K, EQR and UTHR
Neuroblastoma Pipeline Review 2014: 32 Companies & 73 Drug profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pzz2k/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - United Therapeutics Corporation - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Celgene Corporation - AEterna Zentaris Inc. - Lixte Biotechnology Holdings, Inc. - Lorus Therapeutics Inc. - Novogen Limited - Threshold Pharmaceuticals, Inc. - Sareum Holdings plc - MabVax Therapeutics, Inc. - Bionucleon Srl - CerRx, Inc. - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - APEIRON Biologics AG - Xcovery, Inc. - Sutro Biopharma, Inc. - Incuron, LLC - Errant Gene Therapeutics, LLC - DEKK-TEC, Inc. - Bexion Pharmaceuticals, LLC. - Cancer Prevention Pharmaceuticals, Inc. - CureFAKtor Pharmaceuticals. LLC For more information visit http://www.researchandmarkets.com/research/9p...roblastoma
Synthetic Genomics Inc. Signs Collaborative Research and Development Agreement with Lung Biotechnology Inc., a Subsidiary of United Therapeutics Corporation, to Develop Humanized Pig Organs to Revolutionize Transplantation Field
PR Newswire - Tue May 06, 5:00AM CDT
Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Lung Biotechnology Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), today announced they have entered into a multi-year research and development agreement to develop humanized pig organs using synthetic genomic advances. The collaboration will focus upon developing organs for human patients in need of transplantation, with an initial focus on lung diseases. As part of the agreement SGI will receive royalties and milestone incentives from the development and commercialization of the organs.
3 Biotech Stocks Making Big Moves Last Week
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 5:30PM CDT
Biotech investors have been taken on a roller coaster ride over the past few months as stratospheric gains in the fourth and first quarters have been realized to pay tax bills and rebalance to other industries. While Foolish investors should never...
United Therapeutics Set to Possibly Pullback After Yesterday's Rally of 2.25%
Comtex SmarTrend(R) - Mon May 05, 5:02PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $102.14 to a high of $106.70. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $104.83 on volume of 995,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 2.25% Gain
Comtex SmarTrend(R) - Mon May 05, 5:01PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $102.14 to a high of $106.70. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $104.83 on volume of 995,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
United Therapeutics Gains on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 12:10PM CDT
United Therapeutics' (UTHR) first quarter earnings were significantly above expectations.
United Therapeutics Larger Than S&P 500 Component Integrys Energy Group
TheOnlineInvestor.com - Wed Apr 30, 3:47PM CDT
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component United Therapeutics Corp was identified as having a larger market cap than the smaller end of the S&P 500, for example Integrys Energy Group Inc ,...
Look for Shares of United Therapeutics to Potentially Pullback after Yesterday's 6.13% Rise
Comtex SmarTrend(R) - Tue Apr 29, 5:15PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $89.57 to a high of $96.24. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $94.68 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
United Therapeutics Corporation Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 5:00AM CDT
-- Revenues of $289.4 million
12.2% Return Seen to Date on SmarTrend United Therapeutics Call (UTHR)
Comtex SmarTrend(R) - Mon Apr 28, 9:19AM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on January 31st, 2014 at $103.65. In approximately 3 months, United Therapeutics has returned 12.15% as of today's recent price of $91.05.
Technical Roundup on Health Care Stocks -- Research on Amarin, United Therapeutics, Hologic, and NxStage Medical
PR Newswire - Fri Apr 25, 1:10PM CDT
On Thursday, April 24, 2014, the NASDAQ Composite ended at 4,148.34, up 0.52%, the Dow Jones Industrial Average finished the day flat at 16,501.65, and the S&P 500 closed at 1,878.61, up 0.17%. The gains were narrow based as four out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.80, down 0.20%, while the index has advanced 0.39% in the last one month. Investor-Edge has initiated coverage on the following equities: Amarin Corp. PLC (NASDAQ: AMRN), United Therapeutics Corp. (NASDAQ: UTHR), Hologic Inc. (NASDAQ: HOLX) and NxStage Medical Inc. (NASDAQ: NXTM). Free technical research on AMRN, UTHR, HOLX and NXTM can be downloaded upon signing up at:
Product Clearance, Appointments, Upcoming Financial Results, and Clinical Study Results - Analyst Notes on Covidien, Medivation, United Therapeutics, Questcor and CareFusion
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Medivation, Inc. (NASDAQ: MDVN), United Therapeutics Corporation (NASDAQ: UTHR), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1611-100free.
Global Hypertension Drugs Market 2014-2018 with Actelion, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Dominating
M2 - Thu Apr 24, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brq49m/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies. The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/brq49m/global
United Therapeutics Corporation To Announce First Quarter 2014 Financial Results Before Market Open On Tuesday, April 29, 2014
PR Newswire - Tue Apr 22, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2014 financial results before market open on Tuesday, April 29, 2014.
Global Neuroblastoma Clinical Trials Review 2014 - Analysis of 9 Companies
M2 - Wed Apr 16, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfcrvd/neuroblastoma) has announced the addition of the "Neuroblastoma Global Clinical Trials Review, H1, 2014" report to their offering. Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Neuroblastoma Therapeutics Clinical Trials - Progenics Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - APEIRON Biologics AG - United Therapeutics Corporation - Cancer Prevention Pharmaceuticals, Inc. - MabVax Therapeutics, Inc. - Eli Lilly and Company - Celgene Corporation - Biotec Pharmacon ASA For more information visit http://www.researchandmarkets.com/research/hf...roblastoma
United Therapeutics Shares Down 8.1% Since SmarTrend's Sell Call (UTHR)
Comtex SmarTrend(R) - Mon Apr 14, 11:22AM CDT
SmarTrend identified a Downtrend for United Therapeutics (NASDAQ:UTHR) on January 31st, 2014 at $103.65. In approximately 2 months, United Therapeutics has returned 8.15% as of today's recent price of $95.20.
United Therapeutics Rises 3.89% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 09, 4:31PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.93 to a high of $98.45. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $95.28 on volume of 824,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of United Therapeutics to Potentially Pullback after Yesterday's 3.89% Rise
Comtex SmarTrend(R) - Wed Apr 09, 4:31PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $93.93 to a high of $98.45. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high of $95.28 on volume of 824,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
